Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
Circulation. 2023 Apr 18;147(16):1192-1203. doi: 10.1161/CIRCULATIONAHA.122.063399. Epub 2023 Feb 13.
Circulation. 2023.
PMID: 36779348
Clinical Trial.
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG; PRECISION investigators.
Schlaich MP, et al.
Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. Epub 2022 Nov 7.
Lancet. 2022.
PMID: 36356632
Clinical Trial.
Item in Clipboard
The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience.
Bidiuk J, Gaciong ZA, Sobieraj P.
Bidiuk J, et al. Among authors: gaciong za.
Arch Med Sci. 2022 Jun 23;18(4):1095-1099. doi: 10.5114/aoms/150029. eCollection 2022.
Arch Med Sci. 2022.
PMID: 35982912
Free PMC article.
Item in Clipboard
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, Jukema JW, Toth K, Tikkanen MJ, Im K, Wiviott SD, Kurtz CE, Honarpour N, Giugliano RP, Keech AC, Sever PS, Sabatine MS.
Murphy SA, et al. Among authors: gaciong za.
JAMA Cardiol. 2019 Jul 1;4(7):613-619. doi: 10.1001/jamacardio.2019.0886.
JAMA Cardiol. 2019.
PMID: 31116355
Free PMC article.
Clinical Trial.
Item in Clipboard
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators.
Giugliano RP, et al. Among authors: gaciong za.
Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28.
Lancet. 2017.
PMID: 28859947
Free article.
Clinical Trial.
Item in Clipboard
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.
Sabatine MS, et al.
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
N Engl J Med. 2017.
PMID: 28304224
Free article.
Clinical Trial.
Item in Clipboard
ACE genotype and progression of IgA nephropathy.
Gaciong ZA, Religa P, Placha G, Rell K, Paczek L.
Gaciong ZA, et al.
Lancet. 1995 Aug 26;346(8974):570; author reply 571.
Lancet. 1995.
PMID: 7658787
No abstract available.
Item in Clipboard
Cite
Cite